| Cat. No. |
Product Name |
Information |
| PC-Ab1040 |
Utomilumab
|
Utomilumab (PF-05082566) is a ligand-blocking antibody, binds 4-1BB between CRDs 3 and 4, a fully human monoclonal antibody (mAb) agonist that selectively binds to 4-1BB (also called CD137), a protein receptor expressed in many cancer-fighting T cells. Utomilumab (PF-05082566) binds specifically to 4-1BB (CD-137), a receptor protein found in many immune cells, such as T-cells (killer T-cells and helper T-cells) and natural killer cells.. |
| PC-Ab1039 |
Selicrelumab
|
Selicrelumab (RO 7009789) is a fully humanized monoclonal IgG2 antibody that binds CD40 with a very high affinity (Kd=0.4 nM). Selicrelumab does not bind the same site as natural CD40L and hence does not block the natural CD40L-CD40 interaction. Selicrelumab binds to CD40 on a variety of immune cell types. This triggers the cellular proliferation and activation of antigen-presenting cells (APCs), and activates B-cells and T-cells, resulting in an enhanced immune response. Selicrelumab also binds |
| PC-Ab1038 |
Cusatuzumab
|
Cusatuzumab (ARGX-110) is a human αCD70 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity activity, eliminated LSCs in vitro and in xenotransplantation experiments. Cusatuzumab triggers Fc-mediated cytotoxicity with enhanced ADCC and inhibition of CD70/CD27 signaling, resulting in killing of malignant cells such as leukemia blasts and stem cells.. |
| PC-Ab1037 |
Codrituzumab
|
Codrituzumab is a humanized monoclonal antibody targeted at glypican-3 (GPC3), which is a member of the glypican family. Codrituzumab binds to glypican-3 (GPC3). Glypican-3 (GPC3) is highly expressed in hepatocellular carcinoma (HCC). Codrituzumab triggers FcγRIIIa-mediated (CD16-mediated) antibody-dependent cell cytotoxicity (ADCC) and/or antibody-dependent cell phagocytosis.. |
| PC-Ab1036 |
Margetuximab
|
Margetuximab (MGAH22) is a Fc engineered HER2-directed monoclonal antibody, increases activation of innate and adaptive anti-ERBB2 immune responses, relative to trastuzumab. Margetuximab binds to the same epitope as trastuzumab, but its Fc domain has been modified to enhance binding to activating FcγRIIIA (CD16A) and reduce its affinity for inhibitory FcγRIIB (CD32B) receptors.. |
| PC-Ab1035 |
Odronextamab
|
Odronextamab (REGN1979) is a first-in-class, hinge-stabilized, fully human IgG4-based CD3 x CD20 bispecific antibody (bsAb), binds to CD20-expressing cells and CD3 on T cells, targeting CD20+ cells via T-cell-mediated cytotoxicity independent of T-cell receptor recognition. Odronextamab has demonstrated preliminary efficacy in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).. |
| PC-Ab1034 |
Glofitamab
|
Glofitamab is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells a CD20/CD3 antibody (comprising two Fab regions for CD20 and one Fab region for CD3). Glofitamab redirects T cells to engage and eliminate malignant B cells.. |
| PC-Ab1033 |
Bemarituzumab
|
Bemarituzumab (FPA144) is a humanized monoclonal IgG1 antibody against fibroblast growth factor receptor 2b (FGFR2b, FGFR2IIIb), selectively binds to FGFR2b, inhibits ligand binding and mediates antibody-dependent cell-mediated cytotoxicity, recruits natural killer immune cells into the tumor microenvironment to kill the tumor cell in ADCC manner.. |
| PC-Ab1032 |
Oleclumab
|
Oleclumab (MEDI 9447) is a human IgG1 lambda mAb with a triple mutation in the heavy chain constant region for reduced effector function. Oleclumab binds to cluster of differentiation 73 (ecto-5'-nucleotidase) (CD73) and inhibits CD73-associated ectonucleotidase activity, thereby inhibiting the CD73-mediated production of immunosuppressive adenosine. Extracellular adenosine contributes to the immunosuppressive effects of both regulatory T cells and myeloid derived suppressor cells, among others. |
| PC-Ab1031 |
Pembrolizumab
|
Pembrolizumab was the first anti-PD-1 antibody to be approved by the US Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma with disease progression following ipilimumab, and if BRAF (V600) mutation positive, a BRAF inhibitor. Pembrolizumab has also received breakthrough status for the treatment of EGFR mutation-negative, ALK rearrangement-negative non-small cell lung cancer (NSCLC) that has progressed on or following platinum-based chemotherapy. . |
| PC-Ab1030 |
TGN1412
|
TGN1412 is a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. TGN1412 binds to the laterally exposed C′D loop of CD28 and demonstrated its therapeutic potential for use in autoimmune disease, led to a massive and uncontrolled release of proinflammatory cytokines (cytokine storm) during clinical phase I trials.. |
| PC-Ab1029 |
Daclizumab
|
Daclizuma binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). functions as an IL-2 receptor antagonist. Daclizuma specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.. |
